RedShift BioAnalytics

RedShift BioAnalytics Inc. provides advanced analytical instrumentation for the biopharmaceutical and life sciences markets, focusing on protein characterization. The company was established in 2005 as RedShift Systems, initially commercializing semiconductor technology from Princeton University centered on infrared optoelectronic devices. A strategic pivot, assisted by investor Technology Venture Partners (TVP), shifted the company’s focus from being a component manufacturer to developing and producing instruments for protein characterization, leading to its renaming as RedShift BioAnalytics. The founder and current Chief Technology Officer is Eugene Ma.

RedShiftBio operates on a business-to-business model, selling high-value analytical instruments and providing related services directly to biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research laboratories. The company generates revenue through the sale of its instrument platforms—the Aurora, Apollo, and HaLCon systems—and associated reagents and software. Additionally, it offers on-demand analytical services through its StructIR Lab. Its client base includes a majority of the world's leading biopharmaceutical companies.

The core of RedShiftBio's technology is its proprietary Microfluidic Modulation Spectroscopy (MMS), which combines quantum cascade lasers with microfluidics. This technique offers a significant improvement over traditional methods like Fourier-Transform Infrared (FTIR) spectroscopy and Circular Dichroism (CD) by enabling ultra-sensitive and precise measurements of a biomolecule's secondary structure (e.g., alpha-helices and beta-sheets). MMS allows for label-free analysis across a broad concentration range (0.1 to over 200 mg/mL) in complex buffers without the need for sample dilution or buffer exchange. The technology provides critical data on protein structure, stability, aggregation, similarity, and concentration in a single, automated run. The company’s product line includes: the **Aurora and Apollo systems**, fully automated platforms that leverage MMS for in-depth structural analysis of proteins, mRNA, AAVs, and other biomolecules; and the **HaLCon Protein Analyzer**, a liquid chromatography system purpose-built to deliver rapid, HPLC-quality protein titer measurements in under five minutes, streamlining bioprocessing workflows.

The company has secured significant funding through multiple rounds, including a Series C of $11 million in 2017, a Series D of $18 million in 2020, and a Series E of $20 million in 2021, led by notable investors such as Waters Corporation, Illumina Ventures, and Technology Venture Partners. In March 2024, Tom O'Lenic, a seasoned executive with a strong track record in commercializing life science technologies at companies like Unchained Labs and Advanced Cell Diagnostics, was appointed as CEO to drive the next phase of growth.

Keywords: Microfluidic Modulation Spectroscopy, protein characterization, biophysical characterization, life sciences instruments, biopharmaceutical analytics, protein secondary structure, biomolecule analysis, quantum cascade laser, protein stability, protein aggregation, antibody analysis, AAV analysis, mRNA analysis, drug development tools, liquid chromatography, protein titer measurement, bioprocess analytics, formulation development, biosimilarity, automated spectroscopy, label-free analysis, structural biology, high-order structure, biotech instrumentation, RedShiftBio